abstract |
stable formulation, its method of preparation and its use, as well as the use of a mixture of a non-reducing sugar, an anti-(alpha)4(beta)7 antibody and at least one free amino acid. antibody formulations are described comprising a mixture of a non-reducing sugar, an anti-(alpha)4(beta)7 antibody and at least one free amino acid. the disclosed formulations have improved stability, reduced aggregate formation and may delay degradation of the anti-(alpha)4(beta)7 antibody therein or exhibit any combinations thereof. the present invention further provides a safe dosing regimen of these antibody formulations which is easy to follow and which results in a therapeutically effective amount of the anti-(alpha)4(beta)7 antibody in vivo. |